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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver an opinion on EstroG-100TM as a novel food (NF) submitted
pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council. The NF is
EstroG-100TM, a hot-water extract of a mixture of three herbal roots (Cynanchum wilfordii Hemsley,
Phlomis umbrosa Turcz. and Angelica gigas Nakai), which is concentrated and spray-dried. The
information provided on the composition, speciﬁcations and stability of the NF is sufﬁcient, and does
not raise safety concerns. The applicant intends to use EstroG-100TM in food supplements, with a
proposed maximum intake level of 514 mg/day. The target population is post-menopausal women. The
Panel considers that the information provided does not raise safety concerns as regards the
genotoxicity of the NF. The Panel considers that the no-observed-adverse effect level (NOAEL) derived
from the subchronic 90-day oral toxicity study with EstroG-100TM, which was supported by observations
in other studies, is 500 mg/kg body weight (bw) per day. Taking into account the NOAEL and the
proposed maximum intake level, the Panel considers that the margin of safety of 68 is not sufﬁcient.
Based on the absence of chronic toxicity data, increase in effects with exposure duration in toxicity
studies, and the absence of investigations of liver parameters and haematology in human studies, the
Panel applies the uncertainty factor of 200 to derive the maximum safe intake level for the NF. Thus,
the Panel concludes that the NF, EstroG-100TM, is safe for the use in food supplements at the maximum
intake level of 175 mg/day for an adult of 70 kg bw.
© 2016 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver an opinion on EstroG-100TM as a novel food (NF) submitted
pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council. The
assessment follows the methodology set in Commission Recommendation 97/618/EC of 29 July 1997
concerning the scientiﬁc aspects and the presentation of information necessary to support applications
for the placing on the market of novel foods and novel food ingredients and the preparation of initial
assessment reports under Regulation (EC) No 258/97 of the European Parliament and of the Council.
The assessment is based on the data supplied in the original application, the initial assessment by the
competent authority of Ireland, the concerns and objections of the other Member States and the
responses of the applicant.
The NF is EstroG-100TM, an extract of a mixture of three herbal roots: Cynanchum wilfordii Hemsley
(32.5%), Phlomis umbrosa Turcz. (32.5%) and Angelica gigas Nakai (35%). The mixture of the three
herbal roots is hot-water extracted, concentrated and spray-dried.
The information provided on the composition, speciﬁcations and stability of the NF is sufﬁcient and
does not raise safety concerns. The production process is sufﬁciently described and does not raise
concerns about the safety of the NF.
The applicant intends to use EstroG-100TM in food supplements (as tablets, powder, capsules,
softgel or gelcaps). The proposed maximum intake level is 514 mg/day of EstroG-100TM. The target
population is post-menopausal women.
Taking into account the composition of the NF and the intended use levels, the Panel considers that
the NF does not have a nutritionally relevant role in the human diet and that the consumption of the
NF is not nutritionally disadvantageous.
The Panel considers that the information from a bacterial reverse mutation test, in vitro
chromosome aberration test and in vivo micronucleus test does not raise safety concerns as regards
the genotoxicity of the NF.
In a subchronic 90-day repeated dose oral toxicity study, EstroG-100TM was administered to
Sprague–Dawley rats, via oral intubation, at doses of 0, 500, 1,000, or 2,000 mg/kg body weight (bw)
per day. This study reported dose-related effects at the dose of 1,000 mg/kg bw per day (e.g.
increase in albumin, total protein levels, reticulocytes, absolute and relative liver weights). Some of
these effects were also observed in a repeated dose 28-day oral toxicity study with EstroG-100TM and
repeated dose 90-day oral toxicity studies with the single plants which constitute EstroG-100TM. The
Panel considers that the no-observed-adverse effect level (NOAEL) derived from the subchronic 90-day
oral toxicity study with EstroG-100TM, which was supported by observations in the other studies, is
500 mg/kg bw per day.
Two double-blind, placebo-controlled studies in women, who consumed EstroG-100TM or Estromon,
which contained minerals and vitamins in addition to EstroG-100TM, were provided by the applicant.
The Panel considers that these studies do not raise safety concerns with respect to the limited clinical
chemical parameters investigated in relation to EstroG-100TM. However, haematological and liver
effects, which appeared in the toxicological 90-day repeated dose study, have not been investigated in
these studies.
Based on the observations from animal and in vitro studies on potential oestrogenic effect of the
NF, the Panel considers that EstroG-100TM does not exhibit classical oestrogenic effects.
Taking into account the NOAEL of 500 mg/kg bw per day and the proposed maximum intake level
of 514 mg/day for the NF, which corresponds to 7.3 mg/kg bw per day for an adult of 70 kg bw, the
Panel considers that the margin of safety of 68 (i.e. ratio between the NOAEL and the proposed
maximum intake level), is not sufﬁcient. Based on the absence of chronic toxicity data, an increase in
effects with exposure duration in toxicity studies (effects on liver (weight, albumin, total protein) in the
90-day repeated dose study as compared to the 28-day repeated dose study), and the absence of
investigations of liver parameters and haematology in human studies, the Panel applies the uncertainty
factor of 200 to derive the maximum safe intake level for the NF. Thus, by applying the uncertainty
factor of 200 to the NOAEL, the Panel derives the maximum intake level of 2.5 mg/kg bw per day for
the NF, which corresponds to 175 mg/day for an adult of 70 kg bw.
The Panel concludes that the NF, EstroG-100TM, is safe for the use in food supplements at the
maximum intake level of 175 mg/day for an adult of 70 kg bw.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 13 March 2014, the company Naturalendo Tech Co., Ltd submitted a request under Article 4 of
the Novel Food Regulation (EC) No 258/971 to place on the market EstroG-100TM as a novel food (NF).
On 29 July 2014, the competent authority of Ireland forwarded to the Commission its initial
assessment report, which came to the conclusion that EstroG-100TM meets the criteria for acceptance
of a NF deﬁned in Article (3)1 of Regulation (EC) No 258/97.
On 15 September 2014, the Commission forwarded the initial assessment report to the other
Member States (MS). Several of the MS submitted comments or raised objections.
The concerns of a scientiﬁc nature raised by the MS can be summarised as follows:
• The recognised botanical name for ‘Phlomis umbrosa Turcz.’ is ‘Phlomoides umbrosa (Turcz.)
Kamelin & Makhm’ (The Plant List, 2013).
• Information is missing on the origin of the plants used as raw materials and how they were
obtained, on the relevant ingredients of the plants used, on standardisation of the extract
used, and whether hazard-analysis and critical control points (HACCP) concept was applied.
• The speciﬁcations of the NF, which is limited to three ‘markers’, is considered insufﬁcient to
characterise the NF.
• No information has been provided on the presence of other plant-derived compounds (such as
saponins, ﬂavonoids).
• A MS expressed concerns on the presence of potentially toxic compounds in the NF.
• Speciﬁcations for the water used in extraction should be provided.
• The ‘extraction ratio’ for each individual root in the NF is not clearly presented. Furthermore,
different analytical methods are used for the selected markers. The lowest level speciﬁed for
each marker in the NF does not seem to be consistent with the ‘plant-to-extract ratio’.
• No information was provided whether the laboratories where the analyses were conducted
have been accredited under an internationally recognised scheme for the various analyses.
• The stability of the preparation has been set at 3 years, although the moisture of the batches
used in the stability study is unknown.
• A ﬂow chart on the production process for EstroG-100TM is missing.
• Clariﬁcation is needed on the use of methanol as an extraction solvent for the raw materials.
• Although the application refers to the possibility of using freeze-drying, the conditions for this
process have not been described.
• Information on post-marketing surveillance of EstroG-100TM in the countries where it has been
sold (e.g. USA and Canada) is needed.
• Information should be provided on the consumption of the three plants as raw materials for
foodstuffs in Asia.
• Human data on pharmacokinetics of decursin/decursinol angelate, which are compounds in
Angelica gigas Nakai, are required.
• Genotoxicity studies on components, which constitute the NF, should be provided.
• As regards to the subchronic oral toxicity study by Moon et al. (2009), some MS expressed
concerns that the test material used in this study was not equivalent to the NF. The calculated
safety margin between the apparent no-observed-adverse effect level (NOAEL) and the
proposed daily dose of the NF is considerably lower compared to the uncertainty factors
advised by the European Food Safety Authority (EFSA) (http://www.efsa.europa.eu/en/
efsajournal/pub/2579.htm). Therefore, the available toxicity data is insufﬁcient to support a
safe use of the NF as proposed by the applicant.
• The human safety data are restricted to the 12-week study by Chang et al. (2012) as the
study by Lee et al. (2005) was carried out with a different product. The study by Chang et al.
(2012) is considered to be inadequate to identify possible side effects, owing to small size
groups and the short study duration.
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
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• A clinical study with EstroG-100TM in European post-menopausal women, for at least 1 year of
duration, is requested. If the NF is intended to be used by pre- or peri-menopausal women,
reproductive/developmental data are needed.
• There is insufﬁcient information on possible oestrogenic effect of the NF. Possible hormonal
effects of the NF should be examined in appropriate studies, which are recommended in the
OECD Conceptual Framework for Testing and Assessment of Endocrine Disrupters (e.g. studies
to measure oestrogenic activity by means of transactivation assays, proliferation tests on
breast cancer cells, tests for uterotrophic effects).
• No information has been provided on the mode of action of the NF.
• An assessment of the three plants should be undertaken to show the botanical relatedness to
existing food allergens. The potential to elicit reaction in the allergic population also should be
considered. The roots are likely to contain homologues of the major birch pollen allergen Bet v
1 which due to their level of structure and sequence, conservation across plant species are
highly likely to elicit an allergic reaction in sensitised individuals. It is highly likely that the root
of A. gigas Nakai, which is related to Apium graveolens, contains allergens which are likely to
pose a risk to individuals with celery allergy.
• Allergenicity deserves attention and monitoring of allergic effects when the NF is released.
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20022, EFSA is asked to carry out
the additional assessment for EstroG-100TM as a NF in the context of Regulation (EC) No 258/97.
EFSA is asked to carry out the additional assessment and to consider the elements of a scientiﬁc
nature in the comments raised by the other MS.
2. Data and methodologies
2.1. Data
The assessment of the safety of this NF is based on data supplied in the original application, the
initial assessment by the competent authority of Ireland, the concerns and objections of the other MS
and the responses of the applicant.
In accordance with Commission Recommendation 97/618/EC3, EstroG-100TM is allocated to Class
2.2, i.e. foods or food ingredients that are ‘complex novel food from non-genetically modiﬁed source;
the source of the novel food has no history of food use in the Community’. The data are required to
comply with the information required for novel foods of Class 2.2, i.e. structured schemes I, II, III, IX,
XI, XII and XIII of Commission Recommendation 97/618/EC. In the current opinion, these structured
schemes are listed in Sections 3.1–3.9. The intention is to use the NF in food supplements (as tablets,
powder, capsules, softgel or gelcaps). This assessment concerns only risk that might be associated
with consumption of the NF at the proposed conditions of use, and is not an assessment of the
efﬁcacy of EstroG-100TM with regard to any claimed beneﬁt.
2.2. Methodologies
The assessment follows the methodology set out in Commission Recommendation 97/618/EC of
29 July 1997 concerning the scientiﬁc aspects and the presentation of information necessary to
support applications for the placing on the market of novel foods and novel food ingredients and the
preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament
and of the Council.
2 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
3 Commission Recommendation 97/618/EC: Commission Recommendation of 29 July 1997 concerning the scientiﬁc aspects and
the presentation of information necessary to support applications for the placing on the market of novel foods and novel food
ingredients and the preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament and
of the Council. OJ L 253, 16.9.1997, p. 1–36.
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3. Assessment
3.1. Speciﬁcation of the Novel Food (NF)
The NF is EstroG-100TM, an extract of a mixture of three herbal roots: Cynanchum wilfordii Hemsley
(32.5%), Phlomis umbrosa Turcz. (32.5%) and Angelica gigas Nakai (35%). The mixture of the three
herbal roots is hot-water extracted and concentrated, and dried by spray drying.
Cynanchum wilfordii Hemsley (from the former family Asclepiadaceae) is the scientiﬁc name
of this plant. Synonyms are: Cynoctonum wilfordii Maxim., Seutera wilfordii (Maxim.) Pobed.,
Vincetoxicum wilfordii (Maxim.) Franch. & Sav. The plant is also called Cybanchi wilfordi Radix; Ge
Shan Niu Pi Xiao or Baishouwu in China; Baek-ha-su-o or Baek-su-o or Eun-jo-rong in Korea. The used
part of the plant is the root. This plant contains various phytochemicals such as a-methylglaucobioside,
b-methylglaucobioside, b-sitosterol, caudatin, cinnamic acid, cymaronic acid, D-cymarose, deacetyl-
metaplexigenin, glaucogenin A, kidjoranine, L-cymarose, methyleugenol, lineolone, 12-O-cinnamoyl-20-
O-ikemaoyl-sarcostin, 12-O-cinnamoyl-20-O-tigloylsarcostin, penupogenin, sarcostin, wilforibiose and
wilfoside (Jiang et al., 2011; TradiMed database).
The botanical name of Phlomis umbrosa Turcz. (from the Lamiaceae family) is Phlomoides umbrosa
(Turcz.) Kamelin & Makhm. The plant is also called Phlomidis Radix.; Cao su or Xu duan in China and
Sok-dan in Korea. The used part of the plant is the root. P. umbrosa contains various phytochemicals
such as betonicine, shanzhiside methyl ester and succinic acid. Several studies were performed on
P. umbrosa in order to determine the composition of the root (Guo et al., 2001; Liu et al., 2007, 2008,
2009a,b; Deng et al., 2011).
Angelica gigas Nakai (from the Umbelliferae family) is the scientiﬁc name of this plant. The plant is
also called Angelicae gigantis or Dong Quai in China and Dang-gui in Korea. The used part of the plant
is the root. Decursin, decursinol angelate, nodakenin and decursinol have been identiﬁed in A. gigas
(Konoshima et al., 1968; Kim et al., 2006; Cho et al., 2007; Avula et al., 2007; Ahn et al., 2008;
Kim et al., 2011).
Information on the origin of the three plants that are used as raw materials (e.g. place of
cultivation, harvesting, and processing) was provided by the applicant. C. wilfordii Hemsley and
A. gigas Nakai are cultivated and harvested in the central part (Chungcheong province) and eastern
part (Gangwon province) of South Korea and collected by the regional Agricultural Association.
P. umbrosa Turcz. is collected in the central part of South Korea (Chungcheong province) and in China
(Sichuan and Hubei provinces). After being processed (washing, drying, cutting and packaging), the
plants are transported to the manufacturing facilities.
The three main families of compounds present in EstroG-100TM are coumarins, iridoids and phenols.
Each individual root was tested for its identity. The roots were extracted with methanol and
analysed by chromatography against markers, which were representative of each plant: shanzhiside
methyl ester was used as marker of the iridoids class for P. umbrosa Turcz. and nodakenin was used
as a marker of the coumarins class for A. gigas Nakai. For C. wilfordii Hemsley, owing to the absence
of a reference for wilfosides, the applicant proposed to analyse C. wilfordii Hemsley against cinnamic
acid, since its content is proportional to that of wilfoside, which belongs to the class of saponins
(Tsukamoto et al., 1985). For C. wilfordii Hemsley, an alkaline hydrolysis step is added before
extraction with methanol in order to analyse free cinnamic acid liberated from wilfoside by
high-performance liquid chromatography (HPLC). Each individual root was checked for compliance to
speciﬁcations in terms of appearance, each individual marker, loss on drying and heavy metals.
Upon EFSA’s request for clariﬁcations on the identity of the three roots, the applicant indicated that
cinnamic acid, which has been proposed as a speciﬁc marker for C. wilfordii Hemsley, was not
detected in P. umbrosa Turcz. or A. gigas Nakai. However, the applicant acknowledged that cinnamic
acid can be found in other Cynanchum plants (e.g. Cynanchum auriculatum Royle ex Wight). In this
respect, the applicant indicated that the Ministry of Food and Drug Safety of Korea requires analyses
by polymerase chain reaction (PCR) for controlling the absence of C. auriculatum in products derived
from C. wilfordii. The applicant assured that quality controls by PCR are performed on each batch of
the root and that, therefore, the possibility of misuse of C. auriculatum Royle ex Wight is eliminated.
Following an EFSA request for clariﬁcation on the composition and speciﬁcations of EstroG-100TM,
the applicant provided the results on the analyses of several batches of EstroG-100TM for the classes of
compounds which are naturally occurring in the three plants, together with the respective methods of
detection. The applicant indicated that A. gigas Nakai has been suspected to be a source of
methoxsalen (or xanthotoxin or 8-methoxypsoralen – CAS number 298817), which is a furanocoumarin
Safety of EstroG-100TM
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found naturally in several plants (e.g. Ammi majus, Fagara xanthoxylo€ıdes, Citrus bergamia).
Methoxsalen is also found in Angelica archangelica (a different species than the one used in
EstroG-100TM). Methoxsalen is known to induce phototoxic effects. Since the applicant could not
exclude the presence of methoxsalen in the NF, a maximum level has been included in the
speciﬁcation.
The speciﬁcations for the NF and the respective methods of analysis as proposed by the applicant
are presented in Table 1. Test results for ﬁve batches show compliance with the speciﬁcations
(Table 2). The applicant indicated that accredited and validated methods of the Korean Food Code or
from published papers were used in the analyses applied for the speciﬁcations.
Table 1: Proposed speciﬁcations of the NF
Parameter Speciﬁcation Method
Appearance Yellowish brown ﬁne powder Visual
Loss on drying NMT 100 mg/g KFC <9.1.1.1.1>
Assay
Cinnamic acid(a) 0.012–0.039 mg/g HPLC(e)
Shanzhiside methyl ester(b) 0.20–1.55 mg/g HPLC
Nodakenin(c) 3.35–10.61 mg/g HPLC
Methoxsalen(d) NMT 3 mg/g HPLC
Phenols 13.0–40.0 mg/g UV-visible spectrophotometry
Coumarins 13.0–40.0 mg/g UV-visible spectrophotometry
Iridoids 13.0–39.0 mg/g UV-visible spectrophotometry
Saponins 5.0–15.5 mg/g UV-visible spectrophotometry
Nutritive components
Carbohydrates 600–880 mg/g <KFC 9.1.1.4/General Test_Carbohydrate>
Proteins 70–170 mg/g <KFC 9.1.3.1/General Test_Total nitrate and
Crude Protein>
Fats NMT 4 mg/g <KFC 9.1.1.5.1/General Test_Crude Fat>
Microbiological parameters
Total viable plate count NMT 5,000 CFU/g KFC <9.3.5.1>
Total mould and yeast NMT 100 CFU/g KFC <9.3.10>
Coliform bacteria NMT 10 CFU/g KFC <9.3.7.2>
Salmonella Negative/25 g KFC <9.3.11>
Escherichia coli Negative/25 g KFC <9.3.8>
Staphylococcus aureus Negative/25 g KFC <9.3.12>
Heavy metals
Lead NMT 0.65 mg/kg KFC <9.7.1.2.1>
Arsenic NMT 3.0 mg/kg KFC <9.7.1.2.3>
Mercury NMT 0.1 mg/kg KFC <9.7.1.2.4>
Cadmium NMT 1.0 mg/kg KFC <9.7.1.2.2>
CFU: colony forming units; HPLC: high-performance liquid chromatography; KFC: Korean Food Code; LOQ: limit of quantiﬁcation;
NMT: not more than.
(a): LOQ for cinnamic acid: 2.2 x 105 mg/g.
(b): LOQ for shanzhiside methyl ester: 6.1 x 104 mg/g.
(c): LOQ for nodakenin: 4.1 x 104 mg/g.
(d): LOQ for methoxsalen: 8.7 x 104 mg/g.
(e): Alkaline hydrolysis is performed before the HPLC assay is applied.
Safety of EstroG-100TM
www.efsa.europa.eu/efsajournal 8 EFSA Journal 2016;14(10):4589
The Panel considers that the information provided on the composition, the speciﬁcations and the
batch-to-batch variability of the NF is sufﬁcient and does not raise safety concerns.
3.1.1. Stability of the NF
The stability of EstroG-100TM was tested in three batches in a polyethylene ﬁlm in a ﬁbre drum, up
to 3 years, at room temperature. The three markers (cinnamic acid, shanzhiside methyl ester and
nodakenin), coliform bacteria, appearance and loss on drying were the parameters tested. Results
show that EstroG-100TM is stable for a period of 3 years at room temperature. Therefore, the shelf life
of the NF was proposed to be 3 years.
On the basis of the data provided, the nature of product and the low water content, the
Panel considers that the NF is sufﬁciently stable.
3.2. Effect of the production process applied to the NF
The roots of C. wilfordii Hemsley, P. umbrosa Turcz. and A. gigas Nakai, after inspection and testing
for the standard compounds (cinnamic acid for C. wilfordii Hemsley, shanzhiside methyl ester for
P. umbrosa Turcz. and nodakenin for A. gigas Nakai) and contaminants, are weighed in the established
ratio (32.5:32.5:35) and extracted with hot water. Then, the water extract is ﬁltered in order to
Table 2: Analytical results for testing of ﬁve batches of the NF
Parameter Speciﬁcation SE14010 SE14011 SE14012 SE14014
EG-SD01-
140819
Appearance Yellowish brown
ﬁne powder
Complies Complies Complies Complies Complies
Loss on drying (mg/g) NMT 100 36 31.8 39 35 46.7
Assay
Cinnamic acid (mg/g) 0.012–0.039 0.015 0.015 0.018 0.025 0.021
Shanzhiside methyl ester
(mg/g)
0.20–1.55 0.22 0.22 0.22 0.31 0.22
Nodakenin (mg/g) 3.35–10.61 5.33 5.33 5.46 4.28 5.29
Methoxsalen (mg/g) NMT 3 0.130 0.127 0.132 0.124 0.107
Phenols (mg/g) 13.0–40.0 28.0 33.6 28.8 30.3 26.8
Coumarins (mg/g) 13.0–40.0 29.9 33.6 34.4 30.0 35.2
Iridoids (mg/g) 13.0–39.0 25.3 28.5 28.5 38.3 28.3
Saponins (mg/g) 5.0–15.5 8.8 12.0 9.9 9.3 12.0
Nutritive components
Carbohydrates (mg/g) 600–880 814 719 809 789 727
Proteins (mg/g) 70–170 91 136 93 108 136
Fats (mg/g) NMT 4 1 1 1 2 1
Microbiological parameters
Total viable count CFU/g NMT 5,000 200 2,000 750 0 400
Total mould & yeast CFU/g NMT 100 0 0 0 0 0
Coliform bacteria CFU/g NMT 10 Not detected Not detected Not detected Not detected Not detected
Salmonella Negative/25 g Negative Negative Negative Negative Negative
Escherichia coli Negative/25 g Negative Negative Negative Negative Negative
Staphylococcus aureus Negative/25 g Negative Negative Negative Negative Negative
Heavy metals
Lead (mg/kg) NMT 0.65 0.06 0.14 0.13 0.13 0.10
Arsenic (mg/kg) NMT 3.0 0.33 0.26 0.31 0.50 0.35
Mercury (mg/kg) NMT 0.1 0.00 0.00 0.00 0.00 0.00
Cadmium (mg/kg) NMT 1.0 0.01 0.01 0.02 0.02 0.01
CFU: colony forming units; NMT: not more than.
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remove insoluble materials and concentrated and sterilised. Finally, the product is spray-dried. After
the ﬁnal inspections to check for compliance with speciﬁcations, EstroG-100TM is packed.
A ﬂow chart of the manufacturing process has been provided by the applicant.
Noting that the extraction process occurs with hot water, the Panel considers that lipophilic
compounds (such as methyleugenol) would not be expected to be present in the ﬁnal product.
In response to comments from a MS, the applicant indicated that puriﬁed water, which is obtained
by a hyperﬁltration process through reverse osmosis, is the sole solvent used for the extraction
process and no other solvents are used in the manufacturing process for the NF.
In response to comments from a MS, the applicant indicated that the manufacturing facility for
EstroG-100TM follows the Good Manufacturing Practice (GMP) as requested by the Korean Health
Functional Food Act and has been certiﬁed by the Korean Food and Drug Administration (KFDA). The
applicant provided the summary of the HACCP procedures which are applied in the manufacturing
facility.
The Panel considers that the production process is sufﬁciently described and does not raise safety
concerns.
3.3. History of the organism used as a source of the NF
EstroG-100TM is a hot-water extract of a mixture of herbal roots of C. wilfordii Hemsley, P. umbrosa
Turcz. and A. gigas Nakai.
These herbal roots have been described in the medical book Dong-Eui-Bo-Gam, a traditional book
in eastern Asia area, since 1600. These herbal roots are cited in the Korean Food Code 2006.
Cynanchum wilfordii has been used for centuries for traditional herbal food and is classiﬁed as a
raw material for food by KFDA. The oldest record on C. wilfordii Hemsley (named as Baishouwu or He
Shou Wu) is in Kaibao Bencao written in AD 1108, Song Dynasty in China. This plant has been used for
more than 390 years in northern China and Korea. C. wilfordii has been used widely in Korea by
oriental health professionals.
Phlomis umbrosa has been used for centuries for traditional herbal use and is classiﬁed as a raw
material for food by KFDA. P. umbrosa has been used more than 390 years in Ningxia of northern
China and Korea and it has been included in various traditional herbal remedies.
Angelica sinensis has been originally classiﬁed as plant for tea or other drinks by KFDA. The edible
parts are leaf and root. There are three species in eastern Asia which are used as Dang-gui (Dong
Qui): A. sinensis in China, A gigas in Korea, Angelica acutiloba Kitagawa in Japan. A. gigas has been
used more than 390 years in Korea.
3.4. Anticipated intake/extent of use of the NF
The applicant intends to use EstroG-100TM in food supplements (as tablets, powder, capsules,
softgel or gelcaps). The target population is post-menopausal women.
The proposed maximum intake level is 514 mg/day of EstroG-100TM. The serving level of EstroG-
100TM is 257 mg per capsule or tablet which are intended to be consumed twice a day with water.
Since people in the European Union (EU) do not traditionally consume C. wilfordii Hemsley, P. umbrosa
Turcz. or A. gigas Nakai either separately or mixed, the total intake of the extract of the three herbal
roots corresponds to the consumption of EstroG-100TM.
3.5. Information from previous exposure to the NF or its source
The three herbal roots have been used traditionally in Korea in a separate or mixed way.
EstroG-100TM has been on the market in South Korea since 2002. Sales volumes for 1 month
packages of EstroG-100TM have been provided. From a post-marketing surveillance, which has been in
place since 2006, a total of 291 complaints have been received for 10 million of 1 month packages of
EstroG-100TM sold (i.e. 0.0029%). The applicant indicated that neither serious adverse events nor
serious consumer complaints have been reported since 2002 in South Korea. In 2012, EstroG-100TM
was recognised as a functional ingredient for health/functional food by KFDA.
EstroG-100TM was registered in 2010 and 2011 in the USA and Canada, respectively. The applicant
provided sales volumes of EstroG-100TM in the USA and in Canada for 2014. No post-marketing
surveillance is in place in the USA and Canada.
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3.6. Nutritional information on the NF
The applicant provided information on the nutritional composition of 100 g of EstroG-100TM: energy
309.8 kcal, 73.3 g of carbohydrate, 6.2 g of sugars, 12.6 g of crude protein, 0.4 g of crude fat,
169.9 mg of sodium and 18.7 g of dietary ﬁbre.
Taking into account the composition of the NF and the intended use levels, the Panel considers that
the NF does not have a nutritionally relevant role in the human diet and that the consumption of the
NF is not nutritionally disadvantageous.
3.7. Microbiological information on the NF
EstroG-100TM is produced under GMP with good hygienic practices. Batches of the NF were
screened for a range of microbiological contaminants and complied with the speciﬁcations (Table 2).
The Panel considers that the microbiological information provided does not raise safety concerns.
3.8. Toxicological information on the NF
The applicant provided unpublished reports on studies carried out with the NF: a bacterial reverse
mutation test, an in vitro chromosome aberration test, an in vivo micronucleus test, a single-dose
acute toxicity study, and repeated dose 28-day and 90-day oral toxicity studies.
In reply to a request for additional information from EFSA, the applicant performed a literature
search to retrieve safety studies on the three plants that constitute EstroG-100TM, as well as for
constituents of these plants.
In reply to a comment from a MS, the applicant indicated that reproductive/developmental studies
are not deemed to be necessary as EstroG-100TM is intended to be exclusively used by post-
menopausal women.
3.8.1. Absorption, distribution, metabolism and excretion
In reply to a comment from a MS on the need of information on pharmacokinetics of decursin and
its derivatives, the applicant provided three animal studies which reported that decursin and its
derivatives are rapidly absorbed in rats (tmax = 1 h) and excreted at 90% within 36 h (Kim et al.,
2009a; Song et al., 2011).
3.8.2. Genotoxicity
The applicant provided three unpublished reports on studies which investigated the potential
mutagenicity of EstroG-100TM (Biotoxtech Co, 2010a–c). These studies were conducted in compliance
with KFDA principles on good laboratory practice (GLP) and standards on toxicity studies (KFDA,
2009a,b).
In the bacterial reverse mutation test, four Salmonella Typhimurium strains (TA98, TA100, TA1535
and TA1537) and one Escherichia coli strain (WP2uvrA (pKM101)) were exposed to EstroG-100TM at
levels up to 5,000 lg/plate, in the presence or absence of metabolic activation (S9), using the plate-
incorporation and pre-incubation methods (Biotoxtech Co, 2010a). This test consisted of a ‘dose-range
ﬁnding’ and the ‘main study’. No growth inhibition and no precipitation of the test substance were
evident at any dose levels, in the presence or absence of S9. In the ‘main study’, the mean number of
revertant colonies was below the negative control at all doses both in the presence or absence of S9.
This study did not show mutagenicity of EstroG-100TM, at levels up to 5,000 lg/plate, in the presence
or absence of S9.
In the in vitro chromosome aberration test, Chinese Hamster Lung (CHL/IU) cells were incubated
with EstroG-100TM for 6 h, with or without metabolic activation (S9 mix) (short-time treatment) or 24 h
without S9 mix (continuous treatment) (Biotoxtech Co, 2010b). This test consisted of the ‘growth
inhibition study’ and the ‘main study’. In the ‘growth inhibition study’, cytotoxicity was not evident
following short-time and continuous treatments. Precipitation of the test substance was evident at
1,000, 2,500, and 5,000 lg/mL in short-time and continuous treatments. In the ‘main study’, the
frequency of chromosomal aberrations in short-time and continuous treatments was less than 5% at
all dose levels tested (1,250, 2,500 and 5,000 lg/mL). Precipitation of the test substance was evident
at all dose levels in short-time and continuous treatments. This study did not show chromosome
aberrations of EstroG-100TM, at levels up to 5,000 lg/mL, with or without S9 mix.
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In the in vivo micronucleus test (Biotoxtech Co, 2010c), 6–7-week-old mice (Crlj:Ori:CD1(ICR))
were administered EstroG-100TM by oral gavage. This test consisted of the ‘dose-range ﬁnding study’,
the ‘bone marrow collection study’ and the ‘main study’. In the ‘dose-range ﬁnding study’, which tested
dose levels up to 2,000 mg/kg body weight (bw), no treatment related mortality or clinical signs were
reported in any animals at any doses. In the ‘bone marrow collection study’, which tested the dose of
2,000 mg/kg bw, there was no toxicity at the bone marrow and the number of micronucleated
polychromatic erythrocytes (MNPCE) in polychromatic erythrocytes (PCE) did not increase at 24, 48
and 72 h after dosing. In the ‘main study’ mice were given a single dose of 0, 500, 1,000, 2,000 mg/kg
bw of EstroG-100TM and bone marrow cells were collected 24 h after dosing. No statistically signiﬁcant
increases or evidence of a dose-related effect were observed in the number of MNPCE in PCE at any
dose tested as compared to the negative control group. There were no statistically signiﬁcant
differences in the number of PCE’s in any dose as compared to the negative control group. No mortality
or clinical signs were observed in any animal and no statistically signiﬁcant differences in body weights
were observed in any dose as compared to the negative control groups. This study did not show
mutagenic effects of EstroG-100TM, at levels up to 2,000 mg/kg bw. The Panel notes that it has not
been demonstrated that the test material, which is a complex mixture of compounds, reached the bone
marrow. However, the Panel acknowledges the high dose of the material which has been tested in this
in vivo study.
Upon EFSA’s request, the applicant provided one publication and four unpublished study reports on
bacterial reverse mutation tests and in vitro chromosome aberration tests on a water extract of
lyophilised A. gigas root, a micronised powder of C. wilfordii Hemsley and a micronised powder of
P. umbrosa Turcz. (TTC Co, 2013a–d, Yun et al., 2015). Yun et al. (2015) also reported results from an
in vivo micronucleus test where mice were orally given a water extract of lyophilised A. gigas root at
doses up to 2,000 mg/kg bw per day for 4 days. These studies did not show genotoxicity or
mutagenic effects of the plants investigated.
In reply to a comment from a MS and upon EFSA’s request, the applicant provided publications of
genotoxicity studies on compounds from A gigas Nakai (i.e. decursin and decursinol angelate) (Kim
et al., 2009b; Mahat et al., 2012) and compounds from C. wilfordii Hemsley (i.e. esters and alcohols of
cinnamic acid and cinnamyl alcohol) (Belsito et al., 2007). These studies did not show mutagenic
effects of the compounds investigated.
The Panel considers that the information provided does not raise safety concerns as regards the
genotoxicity of the NF.
3.8.3. Acute toxicity studies
The potential toxicity of the NF was investigated in an acute study, in which a single dose of
EstroG-100TM of 0 (water for injection), 1,000, 2,000 or 4,000 mg/kg bw was administered via oral
gavage to Sprague–Dawley rats (Crl:CD(SD)) (5 animals/sex per group) (Biotoxtech Co, 2010d). This
study was conducted in compliance with KFDA principles on GLP and standards on toxicity studies (KFDA,
2009a,b). Compound-coloured stools and/or soft stools, which disappeared on day 2, were observed in
the 4,000 mg/kg bw group only on day 1 after dosing. The authors concluded that the approximate
lethal dose of EstroG-100TM was greater than 4,000 mg/kg under the conditions of this study.
Upon EFSA’s request, the applicant provided acute oral toxicity studies on compounds from A. gigas
Nakai: LD50 of decursin and decursinol angelate in rats was higher than 2,000 mg/kg bw (Kim et al.,
2009c), and of esters and alcohols of cinnamic acid and cinnamyl alcohol, it was 1,520 mg/kg bw and
higher in different species according to a review from Belsito et al. (2007).
3.8.4. Repeated dose toxicity studies
A subchronic 90-day oral toxicity study (Biotoxtech Co, 2015) on EstroG-100TM was provided by
the applicant. This study was conducted in compliance with the OECD (1998) principles on GLP and
the Japanese Guidelines on repeated dose toxicity studies. Sprague–Dawley rats (Crl:CD(SD))
(10 animals/sex per group; post-natal day: 6 weeks) were administered, via oral intubation,
EstroG-100TM at doses of 0 (water vehicle), 500, 1,000, or 2,000 mg/kg bw per day for 90 consecutive
days. These doses were selected based on the results from a repeated dose 28-day oral toxicity study
in rats (TTC Inc., 2015) which reported a statistically signiﬁcant increase in the relative liver weight in
males and females for the two doses of EstroG-100TM tested (i.e. 1,000 and 3,000 mg/kg bw per day).
A summary of the observations from the repeated dose 28- and 90-day oral toxicity studies is provided
in Table 3.
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The 90-day study reported coloured stools, which were probably caused by the study product, in
eight males and four females in the 500 mg/kg bw groups and in all animals in the 1,000 and
2,000 mg/kg bw groups.
Hypersalivation was present sporadically in ﬁve males in the 1,000 mg/kg bw group and in 10
males and four females in the 2,000 mg/kg bw groups after dosing.
Statistically signiﬁcant increases in total urinary excretion of potassium (K) and chloride (Cl) were
noted in males in the 1,000 and 2,000 mg/kg bw groups as compared to the control group.
Dose-related increase in reticulocytes, which was statistically signiﬁcant only in the 1,000 mg group,
was noted in females. A statistically signiﬁcant decrease in erythrocyte count and statistically
signiﬁcant increases of mean corpuscular volume (MCV) and mean corpuscular haemoglobin (MCH)
were noted in females in the 2,000 mg/kg bw group.
Statistically signiﬁcant increases of albumin levels and A/G ratio were noted in males in the
2,000 mg/kg bw group, and statistically signiﬁcant increases of total protein and albumin levels were
noted in females in the 1,000 and 2,000 mg/kg bw groups.
Statistically signiﬁcant increases in the absolute and relative liver weights were noted in females in
the 1,000 and 2,000 mg groups. At necropsy, there was no observation of any macroscopic changes
associated with the intervention. Microscopic examinations of tissues showed no between-group
differences in the incidence of histopathological ﬁndings.
In addition, the applicant provided a subchronic 90-day oral toxicity study which was carried out
with a product (EstroG-200) that contained 40.8% of EstroG-100TM together with minerals and vitamins
(Moon et al., 2009). This study was conducted in compliance with the ICH guideline on chronic toxicity
testing in animals and with the KFDA guideline on safety evaluation of drugs (ICH, 1998; KFDA, 2005).
The results from this study have been summarised in Table 3.
Upon a request by EFSA for additional information, the applicant provided a publication on a
subchronic 90-day oral toxicity study on a water extract of lyophilised A. gigas (AG) root (Yun et al.,
2015), and two unpublished reports on subchronic 90-day oral toxicity studies on a micronised powder
of C. wilfordii Hemsley and P. umbrosa Turcz. (TTC Co, 2013e; Biotoxtech Co, 2016) . The results from
these studies have been summarised in Table 3.
The applicant also provided repeated dose oral toxicity studies on a water extract of lyophilised AG
root at daily doses up to 2,000 mg/kg bw for 14 days (Yun et al., 2015); on decursin at daily doses up
to 250 mg/kg bw for 4 weeks (Jiang et al., 2013); on decursin and decursinol angelate at daily doses
up to 20 mg/kg bw for 30 days (Kim et al., 2009c). The applicant also provided a review on repeated-
exposure oral toxicity studies on esters and alcohols of cinnamic acid and cinnamyl alcohol (Belsito
et al., 2007). These studies did not show toxicity effects of the products investigated.
Table 3: Summary of repeated dose oral toxicity studies for the evaluation of the NF
Substance
Method of
preparation
Dose levels tested
Same dose level as
EstroG-100TM
(mg/kg bw), route
Species strain
n/dose group
Lowest dose with
effect
(statistically
signiﬁcant)
mg/kg bw day
Effect (affected sex)
Subacute 28-day study
EstroG-100TM (TTC
Inc., 2015)
0, 1,000, 3,000
Suspension in water
Oral gavage
Rat (SPF)
Crl:CD(SD)
6 m, 6 f
1,000 Dose related: rel. liver weight ↑ (m,f),
eosinophils ↓ (m)
Not dose related: rel. heart weight ↑ (f)
HCT ↑ (m),
In urine: Na ↑ (m), Cl ↑ (m)
3,000 Rel. kidney weight ↑ (f),
Rel. salivary gland weights ↑ (f)
Creatinine: ↓ (m)
In urine: K ↓ (f)
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Substance
Method of
preparation
Dose levels tested
Same dose level as
EstroG-100TM
(mg/kg bw), route
Species strain
n/dose group
Lowest dose with
effect
(statistically
signiﬁcant)
mg/kg bw day
Effect (affected sex)
Subchronic 90-day studies
EstroG-100TM
(Biotoxtech Co,
2015)
0, 500, 1,000, 2,000
Suspension in water
Oral gavage
Rat
Sprague–Dawley
(Crl:CD(SD))
10 m, 10 f
500 Coloured stools
Not dose related: rel. thymus
weight ↓ (f), rel. spleen weight ↓ (f)
1,000 Dose related: hypersalivation (m
sporadically, at 2,000 m and f); in
urine: K ↑ (m), Cl ↑ (m); albumin ↑ (f),
total protein ↑ (f), reticulocytes ↑(f)
(statistically signiﬁcant only at 1,000),
abs. + rel. liver weights ↑ (f)
2,000 Erythrocytes ↓ (f), MCV ↑ (f), MCH ↑
(f), A/G ratio ↑ (m)
EstroG-200 (which
includes 40.8%
EstroG-100TM, minerals
and vitamins) (Moon
et al., 2009)
0, 250, 500, 1,000 of
EstroG-200 (which
correspond to 0, 103, 206,
412 of EstroG-100TM)
Oral gavage
Suspension in water
Rat
Sprague Dawley
10 m, 10 f
103 Not dose related: creatine kinase ↓ (m),
Ca ↑ (f)
206
412 Ca ↓ (m), abs. brain weight ↓ (m)
Water extract of
lyophilised
Angelica gigas (35%
in EstroG-100TM) (Yun
et al., 2015)
0, 125, 250, 500, 1,000,
2,000 (which correspond to
0, 357, 714, 1,428, 2,857,
5,700 of EstroG-100TM)
Oral gavage
Suspension in water
Rat
F344
10 m, 10 f
357 No effect
714 Dose related: total protein ↑ (m), total
cholesterol ↑ (m), albumin ↑ (m)
Not clearly dose related: MCH ↓ (m)
1,428
2,857 Dose related: Abs. liver weight ↑ (f)
Not dose related: rel. liver weight ↑ (f)
5,700 Abs. kidney weight ↑ (f), AST and
ALT ↓ (m)
Micronised powder of
Cynanchum wilfordii
(32.5% in EstroG-
100TM) (Biotoxtech
Co, 2016)
0, 150, 300, 600 (which
correspond to 0, 462, 923,
1,846 of EstroG-100TM)
Oral gavage
Suspension in water
Rat,
Sprague–Dawley
(Crl:CD(SD))
10 m, 10 f
462 Not dose related:
In urine: Na ↓ (m), K ↓ (m), Cl ↓ (m)
In blood: GGT ↓ (m), Na ↓ (m) partial
thromboplastin time ↓ (m), rel. brain
weight ↓ (f)
923 Dose related: rel. liver weight ↑ (f), rel.
weight seminal vesicles ↑ (m), total
cholesterol ↑ (f), Cl ↑ (m),
Not dose related: total protein ↑ (f),
abs. weight seminal vesicles ↑ (m);
1,846 Abs. + rel. adrenal weight ↑ (f)
1,846
4 weeks recovery
Total cholesterol ↑ (f) epididymis weight
↓ (m), neutrophils ↓ (f)
Micronised powder of
Phlomis umbrosa
(32.5% in EstroG-
100TM) (TTC Co,
2013e)
0, 300, 1,000 (which
correspond to 0, 923,
3,077 of EstroG-100TM)
Oral gavage
Suspension in water
Sprague–Dawley
(Crl:CD(SD))
6 m, 6 f
923 Not dose related: eosinophils ↑ (f)
Inorganic P ↑ (m)
3,077 Partial prothrombin time ↓ (m)
abs: absolute; bw: body weight; Cl: chloride; f: females; GGT: gamma glutamyl transpeptidase; HCT: haematocrit; K: potassium; m: males; MCH:
mean corpuscular haemoglobin; MCV: mean corpuscular volume; Na: sodium; NF: novel food; rel.: relative.
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The Panel notes that the studies provided, which have been summarised in Table 3, did not show
effects on mortality or effects on histopathology up to the high dose levels tested. The changes
observed are in absolute and relative organ weights, clinical chemical parameters, haematology and
urine analysis. In the unpublished 90-day toxicity study with EstroG-100TM (Biotoxtech Co, 2015), no
substance-related ﬁndings, besides coloured stools, are reported at the lowest dose level tested
(500 mg/kg bw). At 1,000 mg/kg bw, several dose-related effects are reported: albumin and total
protein levels are increased in females as well as absolute and relative liver weights, possibly reﬂecting
increased protein synthesis in the liver. Increases in absolute liver weight, total protein and albumin,
which were dose-related, were reported also in the study with a water extract of lyophilised A. gigas
(Yun et al., 2015). Increase in relative liver weight, which was dose-related, was also reported in the
study with a micronised powder of C. wilfordii Hemsley (Biotoxtech Co, 2016). In addition, in the
unpublished 90-day toxicity study with EstroG-100TM (Biotoxtech Co, 2015), dose-related increases in
reticulocytes were seen (20% at 1,000 mg/kg bw). This ﬁnding has to be seen as an adverse effect,
which is supported by the fact that at the next dose level (i.e. 2,000 mg/kg bw), erythrocytes are
decreased (7%) concomitant with an increase in MCV and MCH. Weight changes in seminal vesicles
were reported in the subchronic toxicity study on a micronised powder of C. wilfordii Hemsley (at a
dose corresponding to 923 mg/kg bw of EstroG-100TM). In addition, weight changes were seen in the
epididymides and the adrenals in the high-dose groups (which corresponded to a dose of 1,846 mg/kg
bw of EstroG-100TM). These observations point to possible endocrine effects, but only at high dose
levels.
The Panel considers that the NOAEL derived from the subchronic 90-day oral toxicity study with
EstroG-100TM (Biotoxtech Co, 2015), which was supported by observations in the other studies, is
500 mg/kg bw per day.
3.8.5. Human studies
The applicant provided two human intervention studies (Lee et al., 2005; Chang et al., 2012).
In the double-blind, placebo-controlled study by Lee et al. (2005), 48 women with ‘diagnosed
menopausal syndrome’ (above 45 years of age), from a South Korean hospital, were randomised to
consume either Estromon (n = 24), which contained 40.81% of EstroG-100TM plus minerals and
vitamins, or placebo (n = 24) for 12 months. The consumption of Estromon corresponded to 514 mg/
day of EstroG-100TM.
This study investigated ‘change of climacteric symptoms’ and ‘change in patients with climacteric
symptoms at baseline’ after 3 months of intervention.
This study reported a decrease in serum osteocalcin, alkaline phosphatase (ALP) and triglycerides
levels in the intervention group as compared to the placebo group at 12 months. An increase in the
femoral neck bone mineral density (BMD) and serum human growth hormone levels in the intervention
group as compared to the placebo group at 12 months, were reported. There were no between-group
changes for the other parameters reported (serum oestrogen, follicle stimulating hormone (FSH),
serum total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), spinal bone
density). No weight increase was observed.
The Panel notes that this study, which was carried out with a product containing minerals and
vitamins in addition to EstroG-100TM, did not investigate liver and haematological parameters. No
adverse effects were reported in this study.
In the double-blind, placebo-controlled study by Chang et al. (2012), 64 women (White or African
Americans) with menopausal symptoms (Kupperman menopause index (KMI) ≥ 20) were randomised
to receive either EstroG-100TM (n = 31; 514 mg/day; age range 45–64 years) or placebo (n = 33; age
range 42–70 years) for 12 weeks.
No adverse events were reported by participants. No between-group changes were observed in
weight, body mass index (BMI), serum oestrogen, human growth hormone, osteocalcin, ALP, total
cholesterol, LDL, HDL and triglycerides levels. There was a change in mean serum FSH level between
the two groups, which was probably due to a decrease in the placebo group.
The Panel notes the short duration of this study and the absence of investigations of liver and
haematological parameters.
The Panel considers that the two human studies with an intake of EstroG-100TM of 514 mg/day do
not raise safety concerns with respect to the limited clinical chemical parameters investigated in
relation to EstroG-100TM. However, haematological and liver effects, which appeared in the toxicological
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90-day repeated dose study, have not been investigated. The Panel notes that neither study was
designed to assess the safety of the tested products.
3.8.6. Animal and in vitro studies on possible oestrogenic effects
The applicant provided animal and in vitro studies to address the potential oestrogenic effect of
EstroG-100TM.
3.8.6.1. Animal studies
The possible oestrogenic effect of EstroG-100TM was investigated in two studies with ovariectomised
(OVX) rats (Kim et al., 2008; Lee et al., 2008).
In the study by Kim et al. (2008), 8-week-old Sprague–Dawley rats were ovariectomised and after
3 weeks recovery period they were divided into nine groups (seven rats each group): six groups of
OVX rats received by gavage 73.5, 180, or 440 mg/kg bw per day of EstroG-100TM or Estromon and
the remaining three groups received distilled water (OVX control group, normal control group and
sham control group) for 12 weeks.
There were no statistically signiﬁcant differences in body weight, absolute uterus, liver and kidney
weights between the EstroG-100TM/Estromon groups and OVX control group. There was a statistically
signiﬁcant increase in serum insulin-like growth factor 1 (IGF-1) levels in two EstroG-100TM groups (i.e.
180 and 440 mg/kg bw) (p < 0.05). All the EstroG-100TM groups showed a statistically signiﬁcant
decrease in the serum osteocalcin levels (p < 0.05). A statistically signiﬁcant increase in the femoral
BMD was found in the EstroG-100TM and Estromon groups (p < 0.05). In particular, all EstroG-100TM
groups showed a signiﬁcant dose-dependent increase in bone density (p < 0.05).
In the study by Lee et al. (2008), 51 forty-week-old Sprague–Dawley rats were ovariectomised and
after 3 weeks recovery they were separated into six groups which were administered by gavage
isoﬂavones, EstroG-100TM (at doses of 100 mg/kg bw or 500 mg/kg bw per day), Estromon 100 mg/kg
bw per day, or distilled water (sham and OVX control groups) for 12 weeks.
There was no statistically signiﬁcant difference in body and uterus weight between the
EstroG-100TM/Estromon groups and OVX control group. A statistically signiﬁcant increase in femoral
BMD was observed (p < 0.05) in the 100 mg/kg bw EstroG-100TM group as compared to the OVX
control group.
The Panel notes that OVX rats were exposed to interventions for 12 weeks, which is a longer
period than the 3-day period requested as minimum in the uterotrophic assay by the OECD Guideline
test N. 440 (OECD, 2007). The longer duration would allow detecting oestrogenic substances with
higher sensitivity. The relevant endpoint (i.e. increase in uterine weight) was unchanged, indicating
that there is a lack of oestrogenic activity.
3.8.6.2. In vitro studies
Binding afﬁnity of EstroG-100TM to the oestrogen a and b receptors (ERa and ERb) was investigated
in an in vitro study, where 17-b estradiol was used as a positive control (Research Institute of
Veterinary Medicine, 2008). There was no increase in absorbance, which was associated with binding
afﬁnity to the oestrogen receptors, with EstroG-100TM. The authors concluded that EstroG-100TM has no
afﬁnity to both ERa and ERb. The Panel notes that competing with oestrogen for receptor binding was
not investigated in this study.
The effect of EstroG-100TM and hot-water extracts of each individual root, at concentrations up to
1,000 lg/mL was investigated in the oestrogen-dependent Michigan Cancer Foundation-7 human
breast cancer cells (MCF-7) (Lee and Jeong, 2007). This study reported a dose-dependent growth
inhibition of the MCF-7 cells at high doses of EstroG-100TM as well as of A. gigas Nakai. The
Panel notes that this study did not include a positive control with oestrogen. Therefore, no conclusions
can be drawn for the test system used in this study.
Lee et al. (2008) investigated the effect of EstroG-100TM, and the extracts of each individual root on
ALP activity in Ishikawa and SaOS-2 cells. In these cell lines, ALP activity and expression of mRNA of
ALP can be stimulated by oestrogen. EstroG-100TM was superior in ALP induction as compared to the
individual roots. But all extracts were less active than 1012 M oestrogen.
The Panel notes that EstroG-100TM does not exhibit classical oestrogenic effects. This view is based
on the absence of changes in sex hormone levels in menopausal women, the absence of reactivity of
the uterus in OVX rats and lack of oestrogen binding in receptor binding assays.
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3.9. Allergenicity
According to the applicant, there is no history of allergenicity associated with the use of the three
plants which constitute EstroG-100TM.
As outlined in the proposed speciﬁcations (Table 1), the protein content in EstroG-100TM ranges
between 70 and 170 mg/g.
A MS commented on the risk of allergic reactions in individuals with celery allergy due to the fact
that celery and A. gigas Nakai belong to the same botanical family (i.e. Apiaceae). Since the risk of
allergic reactions in subjects with known celery allergy cannot be excluded, the applicant proposed to
label that EstroG-100TM should not be consumed by individuals with known celery allergy.
Based on the limited data available, the Panel considers that allergic reactions to the NF cannot be
ruled out, but the likelihood is low.
4. Discussion
The NF is EstroG-100TM, an extract of a mixture of three herbal roots: C. wilfordii Hemsley (32.5%),
P. umbrosa Turcz. (32.5%) and Angelica gigas Nakai (35%). The mixture of the three herbal roots is
hot-water extracted and concentrated, and dried by spray drying.
The information provided on the composition, the speciﬁcations, the batch-to-batch variability and
the stability of the NF is sufﬁcient and does not raise safety concerns. The production process is
sufﬁciently described and does not raise concerns about the safety of the NF.
The applicant intends to use EstroG-100TM in food supplements (as tablets, powder, capsules,
softgel or gelcaps). The proposed maximum intake level is 514 mg/day of EstroG-100TM. The target
population is post-menopausal women.
Taking into account the composition of the NF and the intended use levels, the Panel considers that
the NF does not have a nutritionally relevant role in the human diet and that the consumption of the
NF is not nutritionally disadvantageous.
A bacterial reverse mutation test, an in vitro chromosome aberration test and an in vivo
micronucleus test on the NF did not show indications of mutagenicity or chromosome aberrations for
the NF. The same genotoxicity tests were performed on the single plants which constitute EstroG-100TM
and did not show indications of mutagenicity or chromosome aberrations for the plants investigated.
The Panel considers that the information provided does not raise safety concerns as regards the
genotoxicity of the NF.
In a subchronic 90-day repeated dose oral toxicity study, EstroG-100TM was administered to
Sprague–Dawley rats, via oral intubation, at doses of 0, 500, 1,000 or 2,000 mg/kg bw per day. This
study reported dose-related effects at the dose of 1,000 mg/kg bw per day (e.g. increase in albumin,
total protein levels, reticulocytes, absolute and relative liver weights). Some of these effects were also
observed in a repeated dose 28-day oral toxicity study with EstroG-100TM and repeated dose 90-day
oral toxicity studies with the single plants which constitute EstroG-100TM. The Panel considers that the
NOAEL derived from the subchronic 90-day oral toxicity study with EstroG-100TM, which was supported
by observations in the other studies, is 500 mg/kg bw per day.
Two double-blind, placebo-controlled studies in women were provided by the applicant. One study,
which lasted 12 months, was carried out with Estromon, which contained minerals and vitamins in
addition to EstroG-100TM. The second study, which lasted 12 weeks, was carried out with EstroG-100TM.
Both human studies did not raise safety concerns with respect to the limited clinical chemical
parameters investigated. However, haematological and liver effects, which appeared in the
toxicological 90-day repeated dose study, have not been investigated in these studies. The Panel notes
that neither study was designed to assess the safety of the tested products.
Based on the observations from animal and in vitro studies on potential oestrogenic effect of the
NF, the Panel considers that EstroG-100TM does not exhibit classical oestrogenic effects.
Taking into account the NOAEL of 500 mg/kg bw per day and the proposed maximum intake level
of 514 mg/day for the NF, which corresponds to 7.3 mg/kg bw per day for an adult of 70 kg bw
(default body weight value as indicated by the EFSA Scientiﬁc Committee (2012)), the Panel considers
that the margin of safety of 68 (i.e. ratio between the NOAEL and the proposed maximum intake
level), is not sufﬁcient. Based on the absence of chronic toxicity data, an increase in effects with
exposure duration in toxicity studies (effects on liver (weight, albumin, total protein) in the 90-day
repeated dose study as compared to the 28-day repeated dose study), and the absence of
investigations of liver parameters and haematology in human studies, the Panel applies the uncertainty
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factor of 200 to derive the maximum safe intake level for the NF (EFSA Scientiﬁc Committee, 2012).
Thus, by applying the uncertainty factor of 200 to the NOAEL, the Panel derives the maximum intake
level of 2.5 mg/kg bw per day for the NF, which corresponds to 175 mg/day for an adult of 70 kg bw.
5. Conclusions
The Panel concludes that the NF, EstroG-100TM, is safe for the use in food supplements at the
maximum intake level of 175 mg/day for an adult of 70 kg bw.
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientiﬁc opinion on the safety of EstroG-100TM as a novel food ingredient.
SANTE/E6/SH/ks Ref. Ares(2015)1664994, dated 20 April 2015.
2) Dossier ‘Application for the approval of an extract of mixture of three herbal roots
(EstroG-100TM) for use as a novel food ingredient’ received by EFSA on 23 April 2015, which
was submitted by Naturalendo Tech Co., Ltd.
3) On 30 June 2015, during the validation process of the application, EFSA sent a request to
the applicant to provide missing information.
4) Upon a request by EFSA for missing information, on 30 June 2015, EFSA received the
missing information as submitted by the applicant.
5) Initial assessment report carried out by the Food Safety Authority of Ireland: ‘Safety
assessment of an extract of herbal roots (EstroG-100TM).’
6) Member States’ comments and objections.
7) Response by the applicant to the initial assessment report and the Member States’ comments
and objections.
8) Additional data were provided by the applicant on 18 December 2015 and 15 April 2016.
References
Ahn MJ, Lee MK, Kim YC and Sung SH, 2008. The simultaneous determination of coumarins in Angelica gigas root
by high performance liquid chromatography-diode array detector coupled with electrospray ionization/mass
spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 46, 258–266.
Avula B, Joshi VC, Reddy VLN, Choi YW and Khan IA, 2007. Simultaneous determination of eight coumarins in
Angelica gigas and in various other Angelica species by high performance liquid chromatography and
comparative micro-morphology study of Angelica species. Planta Medica, 73, 1509–1516.
Belsito D, Bickers D, Bruze M, Calow P, Greim H, Haniﬁn JM, Rogers AE, Saurat JH, Sipes IG and Tagami H, 2007.
A toxicologic and dermatologic assessment of related esters and alcohols of cinnamic acid and cinnamyl alcohol
when used as fragrance ingredients. Food and Chemical Toxicology, 45(Suppl. 1), S1–S23.
Biotoxtech Co, 2010a (unpublished). Study title: ‘Bacterial reverse mutation test of EstroG-100’. Study No.:
B10157.
Biotoxtech Co, 2010b (unpublished). Study title: ‘In vitro chromosome aberration test of FGF271/EstroG-100 using
mammalian cultured cell’. Study No.: B10158.
Biotoxtech Co, 2010c (unpublished). Study title: ‘In vivo micronucleus test of FGF271/EstroG-100 in mice’.
Study No.: B10159.
Biotoxtech Co, 2010d (unpublished). Study title: ‘Single oral dose toxicity study of EstroG-100 in Sprague-Dawley
rats’. Study No.: B10156.
Biotoxtech Co, 2015 (unpublished). Study title: ‘Thirteen-week repeated oral dose toxicity study of EstroG-100 in
rats’. Study No.: B14433.
Biotoxtech Co, 2016 (unpublished). Study title: ‘Thirteen-week repeated oral dose toxicity study with four-week
recovery period of Cynanchum wilfordii Hemsley in rats’. Study No.: B14431.
Chang A, Kwak BY, Yi K and Kim JS, 2012. The effect of herbal extract (EstroG-100) on pre-, peri- and post-
menopausal women: a randomized double-blind, placebo-controlled study. Phytotherapy Research, 26, 510–
516.
Cho SK, Abd El-Aty AM, Choi JH, Kim MR and Shim JH, 2007. Optimized conditions for the extraction of secondary
volatile metabolites in Angelica roots by accelerated solvent extraction. Journal of Pharmaceutical and
Biomedical Analysis, 44, 1154–1158.
Deng RX, Duan WL, Liu P, Yang YL and Yin WP, 2011. Secondary metabolites from the roots of Phlomis umbrosa.
Journal of Asian Natural Products Research, 13, 230–237.
Safety of EstroG-100TM
www.efsa.europa.eu/efsajournal 18 EFSA Journal 2016;14(10):4589
EFSA Scientiﬁc Committee, 2012. Guidance on selected default values to be used by the EFSA Scientiﬁc
Committee, Scientiﬁc Panels and Units in the absence of actual measured data. EFSA Journal 2012;10(3):2579,
32 pp. doi:10.2903/j.efsa.2012.2579
Guo SJ, Gao LM and Cheng DL, 2001. Iridoids from Phlomis umbrosa. Pharmazie, 56, 178–180.
ICH (International Conference on Harmonisation), 1998. ICH harmonised tripartite guideline: duration of chronic
toxicity testing in animals (rodent and non rodent toxicity testing).
Jiang Y, Choi HG, Li Y, Park YM, Lee JH, Kim DH, Lee JH, Son JK, Na M and Lee SH, 2011. Chemical constituents
of Cynanchum wilfordii and the chemotaxonomy of two species of the family Asclepiadacease, C. wilfordii and
C. auriculatum. Archives of Pharmacal Research, 34, 2021–2027.
Jiang C, Feng J, Zhang J, Han I and Choung S, 2013. Decursin safety from root of Angelica gigas in rats. Journal
of Northeast Agricultural University, 20, 46–51.
KFDA (Korea Food and Drug Administration), 2005. Test guidelines for the safety evaluation of drugs. Notiﬁcation
No. 2005-60.
KFDA (Korea Food and Drug Administration), 2009a. Good laboratory practices. Regulation for nonclinical
laboratory studies. Notiﬁcation No. 2009-183, Korea Food and Drug Administration.
KFDA (Korea Food and Drug Administration), 2009b. Standards of toxicity studies of drugs. Notiﬁcation No. 2009-116.
Kim MR, Abd El-Aty AM, Choi JH, Lee KB and Shim JH, 2006. Identiﬁcation of volatile components in Angelica
species using supercritical-CO2 ﬂuid extraction and solid phase microextraction coupled to gas
chromatography-mass spectrometry. Biomedical Chromatography, 20, 1267–1273.
Kim SN, Li YC, Xu HD, Yi DG, Kim MS, Lee SP, Lee KT, Kim JS, Kwon MS, Chang PS and Kwak BY, 2008.
Phytoestrogenic effects of combined plant extracts on the change of bone metabolism of OVX rats. Korean
Journal of Food Science and Technology, 40, 316–320.
Kim KM, Kim MJ and Kang JS, 2009a. Absorption, distribution, metabolism, and excretion of decursin and
decursinol angelate from Angelica gigas Nakai. Journal of Microbiology and Biotechnology, 19, 1569–1572.
Kim KM, Kim TH, Park YJ, Kim IH and Kang JS, 2009b. Evaluation of the genotoxicity of decursin and decursinol
angelate produced by Angelica gigas Nakai. Molecular and Cellular Toxicology 5, 83–87.
Kim KM, Lee YJ, Hong YG and Kang JS, 2009c. Oral acute and subacute toxicity studies of decursin and decursinol
Angelate of Angelica gigas Nakai. Molecular and Cellular Toxicology, 5, 153–159.
Kim EJ, Kwon J, Park SH, Park C, Seo YB, Shin HK, Kim HK, Lee KS, Choi SY, Ryu do H and Hwang GS, 2011.
Metabolite proﬁling of Angelica gigas from different geographical origins using 1H NMR and UPLC-MS analyses.
Journal of Agricultural and Food Chemistry, 59, 8806–8815.
Konoshima M, Chi HJ and Hata K, 1968. Coumarins from the root of Angelica gigas Nakai. Chemical and
Pharmaceutical Bulletin, 16, 1139–1140.
Lee NJ and Jeong YR, 2007 (unpublished). Effect of EstroG-100TM on the proliferation of MCF-7 cells.
Lee KO, Lee DJ, Kim SM, Je SH, Kim EK, Han HS and Han IK, 2005. Evaluation of the effectiveness and safety of
natural plant extract (Estramon) on perimenopausal women for 1 year. Journal of Korean Society of
Menopause, 591, 1–11.
Lee NJ, Kim GS, Kwak BY, Yi KT, Lee JK, Jeong YR, Lin CM, Kim JS and Kang JK, 2008. Anti-menopausal effect of
the newly-developed phytoestrogen, FGF271, in vitro and in vivo. Laboratory Animal Research, 24, 167–172.
Liu P, Teng J, Zhang YW, Takaishi Y and Duan HQ, 2007. Chemical constituents from rhizome of Phlomis umbrosa.
Yao Xue Xue Bao (Acta Pharmaceutica Sinica), 42, 401–404.
Liu P, Yao Z, Zhang W, Takaishi Y and Duan HQ, 2008. Novel nortriterpenes from Phlomis umbrosa. Chemical and
Pharmaceutical Bulletin, 56, 951–955.
Liu P, Deng R, Duan H and Yin W, 2009a. Chemical constituents from roots of Phlomis umbrosa. Zhongguo Zhong
Yao Za Zhi (China Journal of Chinese Materia Medica), 34, 867–870.
Liu P, Deng RX, Duan HQ, Yin WP and Zhao TZ, 2009b. Phenylethanoid glycosides from the roots of Phlomis
umbrosa. Journal of Asian Natural Products Research, 11, 69–74.
Mahat B, Chae JW, Baek IH, Song GY, Song JS, Cho SK and Kwon KI, 2012. Physicochemical characterization and
toxicity of decursin and their derivatives from Angelica gigas. Biological and Pharmaceutical Bulletin, 35, 1084–
1090.
Moon JH, Lee NJ, Kwak BY, Yi KT, Lee JK, Kim JS, Kim EJ and Kang JK, 2009. Thirteen-week repeated oral dose
toxicity study of EstroG-200 in Sprague-Dawley rats. Laboratory Animal Research, 25, 377–383.
OECD (Organisation for Economic Co-operation and Development), 1998. OECD Principles of good laboratory
practice (as revised in 1997). OECD series on principles of good laboratory practice and compliance monitoring,
number 1, ENV/MC/CHEM(98)17, 41 pp.
OECD (Organisation for Economic Co-operation and Development), 2007. Test No. 440: Uterotrophic bioassay in
rodents: A short-term screening test for oestrogenic properties. In: OECD guidelines for the testing of
chemicals, Section 4: Health effects, 21 pp.
Research Institute of Veterinary Medicine, 2008 (unpublished). Binding afﬁnity of EstroG to ER alpha and beta
using EnBio Estrogen Receptor/Coactivator ligand assay system. College of veterinary medicine, Chungbuk
National University, Korea.
Song JS, Chae JW, Lee KR, Lee BH, Choi EJ, Ahn SH, Kwon KI and Bae MA, 2011. Pharmacokinetic
characterization of decursinol derived from Angelica gigas Nakai in rats. Xenobiotica, 41, 895–902.
Safety of EstroG-100TM
www.efsa.europa.eu/efsajournal 19 EFSA Journal 2016;14(10):4589
The Plant List, 2013. Version 1.1 Published on the Internet. Available online: http://www.theplantlist.org http://
www.theplantlist.org/tpl1.1/record/kew-152628 [Accessed: 11 November 2014].
TradiMed database, Traditional Chinese Medicine DB. Available online: http://eng.tradimed.com/eDrugEtcInfo.asp?
rid=R0995
Tsukamoto S, Hayashi K and Mitsuhashi H, 1985. Studies on the constituents of Asclepiadaceae plant.57. the
structures of 6 glycosides, Wilfoside-C1N, Wilfoside-C2N, Wilfoside-C3N, Wilfoside-C1G, Wilfoside-C2G,
Wilfoside-C3G, with novel sugar chain containing a pair of optically isomeric sugars. Tetrahedron, 41, 927–934.
TTC Co, 2013a (unpublished). Chromosomal aberration test of Cynanchum wilfordii Hemsley using cultured
mammalian cells. Test substance: Cynanchum wilfordii Hemsley. Test Code: 13555.
TTC Co, 2013b (unpublished). Chromosomal aberration test of Phlomis umbrosa Turcz. using cultured mammalian
cells. Test substance: Phlomis umbrosa Turcz. Test Code: 13556.
TTC Co, 2013c (unpublished). Mutagenicity study of Cynanchum wilfordii Hemsley assessed by bacterial reverse
mutation (Ames) test. Test substance: Cynanchum wilfordii Hemsley. Study Code: 13553.
TTC Co, 2013d (unpublished). Mutagenicity study of Phlomis umbrosa Turcz. assessed by bacterial reverse
mutation (Ames) test. Test substance: Phlomis umbrosa Turcz. Study Code: 13554.
TTC Co, 2013e (unpublished). A repeated-dose (91 days) oral toxicity study of Phlomis umbrosa Turcz. in SD rats.
Test substance: Phlomis umbrosa Turcz. Study Code: 13560.
TTC Inc., 2015 (unpublished). Study title: ‘Repeated dose 28-day toxicity Study of EstroG-100 in rats’. Study No.:
B14433.
Yun JW, Che JH, Kwon E, Kim YS, Kim SH, You JR, Kim WH, Kim HH and Kang BC, 2015. Safety evaluation of
Angelica gigas: genotoxicity and 13-weeks oral subchronic toxicity in rats. Regulatory toxicology and
pharmacology, 72, 473–480.
Abbreviations
AG Angelica gigas
ALP alkaline phosphatase
BMD bone mineral density
BMI body mass index
bw body weight
CHL Chinese hamster Lung
FSH follicle stimulating hormone
GGT gamma glutamyl transpeptidase
GLP good laboratory practice
GMP good manufacturing practice
HACCP hazard-analysis and critical control points
HCT haematocrit
HDL high-density lipoprotein
HPLC high-performance liquid chromatography
ICH International Conference on Harmonisation
KFC Korean Food Code
KFDA Korea Food and Drug Administration
KMI Kupperman menopause index
IGF-1 insulin-like growth factor 1
LD50 lethal dose, median
LDL low-density lipoprotein
MCF-7 Michigan Cancer Foundation-7 human breast cancer cells
MCH mean corpuscular haemoglobin
MCV mean corpuscular volume
MNPCE micronucleated polychromatic erythrocytes
MS Member State
NF novel food
NMT not more than
NOAEL no-observed-adverse effect level
OECD Organisation for Economic Co-operation and Development
OVX ovariectomised
PCE polychromatic erythrocytes
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